NICO Corporation Secures New Patent Approvals Supporting Neurosurgical Brain Access Solutions

NICO Corporation continues steady growth of its patent portfolio with the issuance of two new key patents this week supporting its surgical access system and the system’s assembly and method of use in minimally invasive neurosurgery.

NICO currently holds over 250 issued or pending patents, with 60 focusing solely on safe and repeatable non-disruptive access through eloquent areas of the brain with NICO BrainPath®, efficient removal of tumors and clots down a small corridor using the NICO Myriad®, and collection and biological preservation of tumor tissue in the operating room with the Automated Preservation System®.

“Protecting our intellectual property has always been a top priority for NICO,” said Jim Pearson, president and CEO of NICO Corporation. “Our technologies comprise an integrated systems approach to brain surgery that is creating new realities for neurosurgeons. The published evidence associated with our technologies suggest improved surgical outcomes, giving patients new-found hope.”

Pearson added that these two new patent approvals related to safe access to all regions of the brain are key to protecting the company’s unique and revolutionary intellectual property. “We take IP protection of our innovative technologies very seriously and are proud of our proactive approach to protecting the technical advantages our tools offer neurosurgeons and healthcare providers.”

NICO technologies have been featured in more than 170 peer-reviewed published papers with over 550 unique authors from major academic centers. The company is also the sponsor of ENRICH, a 300-patient $10 million randomized controlled clinical trial that seeks to compare outcomes between minimally invasive early surgical intervention of intracerebral hemorrhage clot removal exclusively using NICO technologies and the current medical management standard of care.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version